403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
France Reports Third Infant Death Linked to Baby Formula
(MENAFN) French authorities have confirmed a third infant death potentially connected to baby formula, amid a wave of product recalls affecting Europe.
The Health Ministry’s health crisis center stated, according to a broadcaster, that “three reports of infant deaths have been brought to the attention of French health authorities."
The reports involve children who reportedly consumed formula included in the ongoing recalls. Two of the deaths occurred on Dec. 23 and Jan. 8.
"To date, no causal link has been scientifically established. Judicial investigations are underway regarding these reports," the health crisis center added.
Since late 2025, multiple brands—including Nestlé and Danone—have voluntarily recalled and withdrawn infant formula in France and other countries amid concerns about the potential presence of the toxin cereulide in their products.
The Health Ministry’s health crisis center stated, according to a broadcaster, that “three reports of infant deaths have been brought to the attention of French health authorities."
The reports involve children who reportedly consumed formula included in the ongoing recalls. Two of the deaths occurred on Dec. 23 and Jan. 8.
"To date, no causal link has been scientifically established. Judicial investigations are underway regarding these reports," the health crisis center added.
Since late 2025, multiple brands—including Nestlé and Danone—have voluntarily recalled and withdrawn infant formula in France and other countries amid concerns about the potential presence of the toxin cereulide in their products.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment